media – Page 190 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Taking advantage of the “Eight Measures of Science and Technology”, Haier Health aims to create a flagship of biotechnology

Query the real-time market situation of the stock, uncover in-depth data on fund flow, and enter Shanghai Laishi Bar. Shanghai Laishi Fund Flow Related Stocks Yongshun Biotechnology (0.000%) Ternary Gene (0.000%) Kangle Defender (0.000%) Oukang Pharmaceutical (0.000%) Related sections Biological products (0.00%) Standard&Poor’s (0.00%) FTSE Russell (0.00%) In vitro diagnostics (0.00%) The first step in stock trading is to open a stock account On the evening of December 22nd, Qingdao Haier Biomedical Co., Ltd. (“Haier Biotech”, 688139. SH) issued a suspension notice regarding the planning of a major asset restructuring. According to the announcement, Haier Biology and Shanghai Laishi Blood Products Co., Ltd. (“Shanghai Laishi”, 002252. SZ) are both listed companies controlled by Haier Group. The two parties have signed an “Absorption and Merger Intention Agreement”, in which Haier Biology will absorb and merge Shanghai Laishi by issuing A-shares to all shareholders of Shanghai Laishi, and raise matching funds through ...
- Source: drugdu
- 632
- December 24, 2024
Beware of “two sets of prices” providing funding sources for pharmaceutical bribery

On December 20th, the National Medical Insurance Bureau sent a letter to the medical insurance bureaus of various provinces, autonomous regions, municipalities directly under the central government, and Xinjiang Production and Construction Corps in response to the investigation of the false invoicing case in the pharmaceutical field by the public security department, requesting a serious investigation into whether there were similar problems with the products involved, such as Ginkgo biloba extract injection, Cefotaxime sodium injection, hydrolyzed protein oral solution, etc., and to quickly determine the bottom line of the listed prices. The National Healthcare Security Administration stated in the letter that it firmly opposes the increase in patient burden caused by inflated drug prices, the formation of illegal profit chains through false invoicing, and illegal and irregular behaviors such as “double pricing of one drug” and “selling with money”. (December 22, People’s Daily Online) Recently, the Economic Reference Daily reported ...
- Source: drugdu
- 577
- December 24, 2024
Is placebo effective? Vertex evaporates $13 billion overnight

On December 19, 2024, Vertex announced that its non opioid painkiller suzetrigine (VX-548) had achieved the primary endpoint of significantly reducing pain in the Phase 2 Sciatica (LSR) study. However, the placebo group also showed significant pain relief (about 2 points), and the difference between the treatment group and the placebo group was not significant. Affected by this news, Vertex’s stock price plummeted by 11.37%. 01. Background VX-548 is a selective NaV1.8 pain signal inhibitor under development, aimed at blocking the transmission of pain signals to the brain by specifically blocking sodium channels in peripheral nerves. Due to its mechanism of action being limited to the peripheral nervous system, VX-548 does not pose an addiction risk to opioid drugs. Previously (December 2023), Vertex retrieved phase 2 clinical data on VX-548 for chronic pain, which showed that its efficacy was comparable to that of the control group Pregabalin. This study further ...
- Source: drugdu
- 505
- December 24, 2024
Aadi Biosciences and WuXi Biologics collaborate to develop 3 new ADC drugs

On December 20, 2024, WuXi Biologics announced that Nasdaq listed biotechnology company Aadi Biosciences had reached a cooperation agreement with WuXi Biologics and Duoxi Biologics to jointly develop three new generation ADC drugs in the preclinical stage, using WuXi Biologics’ antibody discovery technology platform and Duoxi Biologics’ linker payload technology. Aadi Biosciences paid a prepayment of $44 million, a development milestone of $265 million, a commercial milestone of $540 million, and a single digit sales share to WuXi Biologics and Duoxi Biologics, with a total agreement amount of $849 million. Affected by this news, the stock price of Aadi Biosciences surged 63% after trading. Aadi Biosciences had long focused on drug development in the mTOR pathway. Aadi Biosciences’ sirolimus albumin received FDA approval for marketing in 2021, with cumulative sales of $45 million in the first half of this year. As of the end of June this year, Aadi Biosciences ...
- Source: drugdu
- 412
- December 24, 2024
Novo Nordisk’s talent war

Novo Nordisk’s success has not only driven Denmark’s economic growth, but also led to an increasingly fierce talent war in the local labor market. As of September this year, the company employed about 32,000 employees across Denmark, and the number of employees has increased by 75% in less than three years. How exaggerated is Novo Nordisk’s talent war? Because Novo Nordisk offers higher salaries and more attractive career opportunities, many small businesses are forced to close or relocate because they cannot compete with it. For example, Flint Auto, a car service shop in Kalundborg, was forced to close because employees jumped to Novo Nordisk. Construction-related industries are facing a loss of talent, and many companies have to refuse orders due to lack of employees. The clinical microbiology department of a local hospital lost about 10 employees to Novo Nordisk in two years, and it was difficult to recruit new people. ...
- Source: drugdu
- 315
- December 24, 2024
The result exceeded expectations, but AstraZeneca’s “life-saving drug” was still rejected by the FDA

Recently, AstraZeneca announced that the FDA rejected the full approval of its drug Andexxa. It is worth mentioning that the drug was applied for listing in China in December last year. In 2018, Andexxa was approved by the FDA for accelerated listing in the United States, and the following year it won conditional approval from the European Union for the treatment of acute bleeding complications caused by apixaban and rivaroxaban. It is the first and only treatment method that can specifically reverse the activity of FXa inhibitors and achieve hemostasis. It can be said to be a “life-saving drug” in clinical practice. In 2021, AstraZeneca acquired the rare disease giant Alexion for US$39 billion, and Andexxa became a drug under AstraZeneca. Last year, Andexxa contributed US$182 million in sales to AstraZeneca, a year-on-year increase of 23%. In its reply letter, the FDA pointed out that the rejection was because the ...
- Source: drugdu
- 683
- December 24, 2024
AD market is worth hundreds of billions. Can Eli Lilly catch up?

On December 18, Eli Lilly announced that the application for the listing of Donanemab injection (Donanemab) has been approved by the China National Medical Products Administration for the treatment of mild cognitive impairment and mild dementia caused by Alzheimer’s disease in adults. This is another blockbuster new drug in the field of Alzheimer’s disease (AD) treatment after Lencanerizumab, which was approved by Eisai in January this year. In the past, drugs for the treatment of AD were mainly symptomatic treatments, including memantine, donepezil, etc., which symptomatically treated mild, moderate and severe AD. Lencanerizumab and Donanemab, which were launched this year, are targeted treatments for causes. ▍Crossing the Death Valley of Drug Development The research on new drugs for Alzheimer’s disease has always been called the “Death Valley” of drug development. According to a study published by Scientific American magazine, the development of new AD drugs has a high failure rate ...
- Source: drugdu
- 340
- December 24, 2024
Prediction of global best-selling drugs in 2025, tumors, metabolism and other fields are still popular

The journal Nature Reviews Drug Discovery published the prediction of the top 10 global best-selling drugs in 2025. Pembrolizumab, commonly known as “K drug”, topped the list, followed by semaglutide, which has been popular in the field of weight loss in recent years, and its “rival” dual-target telpotide, which is consistent with the sales performance of these drugs in the first three quarters of this year. Among the top ten lists, 4 GLP-1 products entered the forecast list, all of which belong to the field of metabolic therapy. In addition, Dupixent (dupixentumab) and Skyrizi (lishengqizumab), two autoimmune drugs that are frequent guests on the best-selling drug list, are still on the list, ranking 4th and 5th. ▍With a wide range of indications, “K drug” is expected to become the “king of medicine” again In the 2025 forecast, “K drug” still ranks first. In 2023, the global sales of K drug ...
- Source: drugdu
- 1,029
- December 24, 2024
TIHE

Organiser：ITE Group Plc (UK) Time：April 15 – 17, 2025 Address：5, Furkat str., Shaykhontour district, Tashkent Exhibition hall：Navruz Palace Product range: Pharmaceuticals, herbal preparations, nutritional supplements including minerals and vitamins, dietary nutrition products, homeopathic preparations, dermatological preparations, maternal and child healthcare products and infant formula, personal hygiene products, incontinence products, medical consumables, pharmaceutical manufacturing and equipment, medical devices, laboratory equipment and instruments, medical electronic equipment, surgical instruments, ophthalmic equipment and protective products, emergency and first-aid equipment, hospital, dental, and medical facilities About TIHE： The Tashkent International Healthcare Exhibition (TIHE) is a renowned professional medical exhibition in Central Asia. It has significantly promoted the development of the medical and pharmaceutical industries in Uzbekistan and Central Asia, establishing the region as one of the markets with the greatest development potential. TIHE is held concurrently with the Uzbekistan Dental Exhibition. Since its inception, it has received strong support from the Ministry of ...
- Source: drugdu
- 392
- December 24, 2024
Merck’s long-acting RSV antibody therapy submitted for marketing application

Reducing RSV-related hospitalization rates by more than 80%, FDA accepts Merck’s long-acting antibody therapy marketing application Merck (MSD) announced today that the U.S. FDA has accepted the company’s biologics license application (BLA) for the investigational preventive long-acting monoclonal antibody clesrovimab (MK-1654), which is designed to protect infants from RSV disease during their first respiratory syncytial virus (RSV) season. The FDA is scheduled to complete the review by June 10, 2025. Clesrovimab is an extended half-life monoclonal antibody under investigation for the prevention of RSV disease as a passive immunization method. The application is based on the results of the pivotal Phase 2b/3 clinical trial CLEVER, a randomized, placebo-controlled trial evaluating the effect of a single dose of clesrovimab in healthy premature and full-term infants; and interim results of the ongoing Phase 3 clinical trial SMART, which evaluates the safety and efficacy of clesrovimab compared with palivizumab in high-risk infants and ...
- Source: drugdu
- 191
- December 23, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.